Objective:

To report the FDA's approval of exagamglogene autotemcel (CASGEVY) for younger patients with sickle cell disease and transfusion-dependent beta thalassemia.

Approach:

• Therapy Description: CASGEVY is a nonviral, ex vivo CRISPR/Cas9 gene-edited cell therapy that modifies hematopoietic stem and progenitor cells to increase fetal hemoglobin production.
• Clinical Trials: The therapy's efficacy was evaluated in phase 1/2/3 studies (CLIMB-111 and CLIMB-121) for patients aged 12 to 35, with ongoing studies (CLIMB-141 and CLIMB-151) for those aged 2 to 11.

Key Findings:

• The therapy reduces transfusion requirements in patients with transfusion-dependent beta thalassemia.
• Approximately 5,500 additional pediatric patients in the US are now eligible for treatment.

Interpretation:

Limitations:

• Warnings include neutrophil engraftment failure, delayed platelet engraftment, hypersensitivity reactions, and potential off-target genome editing.
• All treated patients experienced grade 3 or 4 neutropenia and thrombocytopenia.

Conclusion:

Sources:

• Vertex Pharmaceuticals